Results 31 to 40 of about 79,234 (272)

Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes

open access: yesHaematologica, 2012
Patient and physician characteristics associated with use of erythropoiesis-stimulating agents in myelodysplastic syndrome patients have not yet been described.
Amy J. Davidoff   +7 more
doaj   +1 more source

Optimization of anemia treatment in hemodialysis patients via reinforcement learning [PDF]

open access: yesArtificial Intelligence in Medicine, Volume 62, Issue 1, September 2014, Pages 47-60, 2015
Objective: Anemia is a frequent comorbidity in hemodialysis patients that can be successfully treated by administering erythropoiesis-stimulating agents (ESAs). ESAs dosing is currently based on clinical protocols that often do not account for the high inter- and intra-individual variability in the patient's response.
arxiv   +1 more source

Suppression of erythropoiesis by actinomycin D. 3. The effect of actinomycin D on the hemoglobin level of bone marrow erythrocytes and erythroblasts [PDF]

open access: yes, 1969
For the purpose of revealing whether or not hemoglobin synthesis is inhibited by the AMD, the author estimated the hemoglobin level of AMD treated anilmals by microspectrophotometer, and found that the hemoglobin levels of all the developmental stages of
Okada, Shigeru
core   +1 more source

Erythropoiesis and Hyperoxia

open access: yesExperimental Biology and Medicine, 1973
SummaryExposure to a 50% oxygen environment produced a decrease in erythropoiesis which was paralleled by a decrease in plasma erythropoietic stimulating activity. Similar results were obtained following exposure to a 100% oxygen environment. Marrow depression produced by hyperoxia could be reversed by erythropoietic stimulants.
Robert M. Donati   +3 more
openaire   +3 more sources

Data-Driven Modeling and Control of Complex Dynamical Systems Arising in Renal Anemia Therapy [PDF]

open access: yesarXiv, 2021
This project is based on a mathematical model of erythropoiesis for anemia, which consists of five hyperbolic population equations describing the production of red blood cells under treatment with epoetin-alfa (EPO). Extended dynamic mode decomposition (EDMD) is utilized to approximate the non-linear dynamical systems by linear ones.
arxiv  

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. [PDF]

open access: yes, 2019
PURPOSE: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.
Bohlius, Julia   +12 more
core   +3 more sources

The TAM receptor tyrosine kinases Axl and Mer drive the maintenance of highly phagocytic macrophages

open access: yesFrontiers in Immunology, 2022
Many apoptotic thymocytes are generated during the course of T cell selection in the thymus, yet the machinery through which these dead cells are recognized and phagocytically cleared is incompletely understood.
Lidia Jiménez-García   +6 more
doaj   +1 more source

Erythropoiesis in Hypothyroidism

open access: yesExperimental Biology and Medicine, 1973
SummaryThe purpose of this study was to clarify the role which disordered iron metabolism and alterations in the homeostatic regulation of red cell production play in hypothyroid anemia.
James W. Fletcher   +3 more
openaire   +2 more sources

Differential Impact of SARS-CoV-2 Isolates, Namely, the Wuhan Strain, Delta, and Omicron Variants on Erythropoiesis

open access: yesMicrobiology Spectrum, 2022
SARS-CoV-2 variants exhibit different viral transmissibility and disease severity. However, their impact on erythropoiesis has not been investigated. Here, we show SARS-CoV-2 variants differentially affect erythropoiesis.
Suguru Saito   +5 more
doaj   +1 more source

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer : randomized clinical trial [PDF]

open access: yes, 2013
BACKGROUND: The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin ...
Bois, Andreas du   +13 more
core   +1 more source

Home - About - Disclaimer - Privacy